1. Generics Bulletin
  2. >>Products

JB Chemicals Sustains Revenue Momentum For Another Quarter

Company Sees ‘Market Beating Growth’ In India

 
• By Akriti Seth

India’s JB Chemicals has seen double-digit growth in its international business and “market beating growth” in its domestic business. The company continues to perform well on the back of new launches, despite COVID-related headwinds. 

India
JB Chemicals sees domestic and international growth • Source: Alamy

JB Chemicals has recorded a growth of 34% in net revenues to INR5.93bn ($80m) for its financial second quarter ending 30 September 2021, driven by increases in both its domestic and international businesses. Sustaining its revenue momentum for yet another quarter, the company also reported a 27% increase in its earnings before interest, tax, depreciation and amortization to INR1.4bn in Q2 FY22.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Products

J&J Denied Injunction Over Private-Label Ustekinumab In US

 
• By Dave Wallace

Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.

UK Forxiga SPCs Wiped Out As Trio Succeed With Plausibility Attack

 
• By Dean Rudge

Generic competition to AstraZeneca’s blockbuster SGLT2 inhibitor Forxiga (dapagliflozin) treatment for diabetes may hit England and Wales earlier than 2028 after a pair of SPCs were invalidated following proceedings initiated by a trio of generics manufacturers.

What’s Next? Five Things To Look Out For In May

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for May 2025.